Extended repertoire of permissible peptide ligands for HLA-B*2702

Protein Science

Volumn 5, Issue 10, 1996, Pages 2080-2088

  Raghavan, Malini ^a   Lebrón, José A ^a   Johnson, Jennifer L ^a   Bjorkman, Pamela J ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

autoimmune disease; binding; HLA B27; peptides; structure based design; unnatural amino acids

Indexed keywords

HLA B ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTHRITIS; ARTICLE; COMPLEX FORMATION; DRUG RECEPTOR BINDING; ENDOPLASMIC RETICULUM; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANIMALIA;

EID: 0029970715     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560051014     Document Type: Article

References (38)

1. Adorini L, Barnaba V, Bona C, Celada F, Lanzavecchia A, Sercarz E, Suciu-Foca N, Wekerle H. 1990. New perspectives on immunointervention in autoimmune diseases. Immunology Today 11:383-387.
2. Bebbington CR, Hentschel CCG. 1987. The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells. In: Glover DM, ed. DNA cloning: A practical approach. Oxford: IRL Press, pp 163-188.
3. Benjamin R, Parham P. 1990. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunology Today 11:137-142.
4. Bjorkman PJ, Parham P. 1990. Structure, function and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem 90:253-288.
5. Bodmer WF. 1978. The HLA system: Introduction. Br Medical Bull 34:213-216.
6. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD. 1973. Ankylosing spondylitis and HLA-B27. Lancet 1:904-907.
7. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD. 1974. Reiters disease and HLA-B27. Lancet 11:996-998.
8. Buxton SE, Benjamin RJ, Clayberger C, Parham P, Krensky AM. 1992. Anchoring pockets in human histocompatibility complex leukocyte antigen (HLA) class I molecules: Analysis of the conserved B ("45") pocket of HLA-B27. J Exp Med 175:809
9. Chen BP, Parham P. 1989. Direct binding of influenza peptides to class-I HLA molecules. Nature 337:742-745.
10. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
11. Fahnestock ML, Johnson JL, Feldman RMR, Tsomides TJ, Mayer J, Narhi LO, Bjorkman PJ. 1994. Effects of peptide length and composition on binding to an empty class I MHC heterodimer. Biochemistry 33:8149-8158.
12. Fahnestock ML, Tamir I, Narhi L, Bjorkman PJ. 1992. Thermal stability comparison of purified empty and peptide filled forms of a class I MHC molecule. Science 258:1658-1662.
13. Feltkamp TEW, Khan MA, Lopez de Castro JA. 1996. The pathogenic role of HLA-B27. Immunology Today 17:5.
14. Gastinel LN, Simister NE, Bjorkman PJ. 1992. Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules. Proc Natl Acad Sci USA 89:638-642.
15. Gaston JSH. 1990. How does HLA-B27 confer susceptibility to inflammatory arthritis? Clin Exp Immunol 82:1-2.
16. Gilliland BC. 1987. Harrison's principles of internal medicine. McGraw Hill, pp 1434-1436.
17. Hammer RW, Maika SD, Richardson JA, Tang JP, Taurog JD. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: An animal model of HLA-B27-associated human disorders. Cell 63:1099-1112.
18. Heeb NV, Aberle AM, Nambiar KP. 1994. Synthesis of enantiomerically pure N-Fmoc-S-Mob-(S)-α-amino-ε-mercaptohexanoic acid and its use in solid phase peptide synthesis. Tetrahedron Lett 35:2287.
19. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. 1991. Identification of self peptides bound to purified HLA-B27. Nature 353:325-330.
20. Khilko SN, Corr M, Boyd LF, Lees A, Inman JK, Margulies DH. 1993. Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. J Biol Chem 268:15425-15434.
21. Lin AY, Devaux B, Green A, Sagerström C, Elliott JF, Davis MM. 1990. Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science 249:677-679.
22. Madden DR, Garboczi DN, Wiley DC. 1993. The antigenic identity of peptideMHC complexes: A comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693-708.
23. Madden DR, Gorga JC, Strominger JL, Wiley DC. 1991. The structure of HLA-B27 reveal nonamer self-peptides bound in an extended conformation. Nature 353:321-325.
24. Madden DR, Gorga JC, Strominger JL, Wiley DC. 1992. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70:1035-1048.
25. Marrack P, Kappler J. 1987. The T cell receptor. Science 235:1073-1080.
26. McMichael AJ, Bell J. 1991. HLA-B27: A disease-associated immune response gene. Res Immunol 142:475-482.
27. Müller R. 1983. Determination of affinity and specificity of anti-hapten anti-bodies by competitive radioimmunoassay. Methods Enzymol 92:589-601.
28. Parham P. 1979. Purification of immunologically active HLA-A and -B antigens by a series of monoclonal antibody columns. J Biol Chem 254:8709-8712.
29. 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J Immunol 149:1896-1904.
30. Qin S, Cobbold SP, Benjamin RJ, Waldmann H. 1989. Induction of classical transplantation tolerance in the adult. J Exp Med 169:779-794.
31. Rammensee HG, Falk K, Rötzschke O. 1993. MHC molecules as peptide receptors. Curr Opin Immunol 5:35-44.
32. Richardson JS. 1981. The anatomy and taxonomy of protein structure. Adv Protein Chem 34:167-339.
33. Rötzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. 1994. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and HLA-B*2705 peptide motifs. Immunogenetics 39:74-77.
34. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929-937.
35. Stern LJ, Wiley DC. 1994. Antigenic peptide binding by class I and class II histocompatibilily proteins. Structure 15:245-251.
36. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, McDevitt HO. 1988. A molecular basis for MHC class II-associated autoimmunity. Science 240:1003-1009.
37. Townsend A, Bodmer H. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601-624.
38. Villadangos JA, Galocha B, Garcia F, Albar JP, López de Castro JA. 1995. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 25:2370-2377.